The purpose of the study was to develop an optimized thermoreversible in situ gel of amide group anesthetic agent for delivery into periodontal pocket containing bupivacaine hydrochloride as a model drug. The prepared formulations are biocompatible and display low viscosity at the moment of in vivo application. once applied, formulation undergo a sol-gel transition , resulting in semisolid gel.Thermosensitive in situ gel containing 5% w/v bupivacaine hydrochloride was formulated by cold method using different combination of pluronic F 127 and F 68 . The gels were evaluated for drug content, gelation temperature, viscosity, invitro release and in vivo evaluation of safety and efficacy of optimized formulation. The gelation of system at body temperature is important evaluation parameter in optimization study. The formulations containing 18% w/v of Pluronic F 127 and 10% w/v of pluronic F 68 showed gelation near to body temperature. The drug release from the formulations was diffusion controlled without swelling. In vivo evaluation of optimized formulation was carried in patient with periodontitis; study was randomized parallel group, double-blind clinical trial. Optimized formulation AF3 showed promising finding in management of pain associated with scaling and root planning. Site specific delivery of anesthesia with longer duration of action was achieved with thermoreversible gel.
Loading....